These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37561368)

  • 21. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between drug lag and factors associated with clinical trials in Japan.
    Ohwaki K; Nakabayashi T
    J Clin Pharm Ther; 2014 Dec; 39(6):649-52. PubMed ID: 25200123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delays in neurological drug development in Japan.
    Shimazawa R; Ikeda M
    Intern Med; 2011; 50(15):1565-8. PubMed ID: 21804282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug Lag.
    Kogure S; Koyama N; Hidaka S
    J Clin Pharmacol; 2017 Nov; 57(11):1479-1490. PubMed ID: 28628225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union.
    Alnuhait M; Alshammari A; Alharbi M; AlOtaibi L; Alharbi R; Khobrani A; Alkhudair N; Alshamrani M; Alrajhi AM
    Ther Innov Regul Sci; 2024 Jul; 58(4):678-686. PubMed ID: 38536660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.
    Matsuda K; Nagai S; Sugimoto K
    Jpn J Clin Oncol; 2023 Dec; 53(12):1125-1129. PubMed ID: 37642224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.
    Cho I; Han E
    Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Empirical Analysis of Japan's Drug Development Lag Behind the United States.
    Nakamura H; Wakutsu N; Murayama S; Suzuki T
    J Clin Pharmacol; 2022 Jul; 62(7):847-854. PubMed ID: 34970781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delays in psychiatric drug development in Japan.
    Shimazawa R; Kusumi I; Ikeda M
    J Clin Pharm Ther; 2012 Jun; 37(3):348-51. PubMed ID: 22017294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West.
    Okabayashi S; Kobayashi T; Hibi T
    Inflamm Intest Dis; 2018 Nov; 3(1):25-31. PubMed ID: 30505839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
    Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
    Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs.
    Hirai T; Suzuki A; Yamori T; Matsuura M
    Invest New Drugs; 2022 Feb; 40(1):142-150. PubMed ID: 34417913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.
    Nakayama H; Tsukamoto K
    Invest New Drugs; 2018 Aug; 36(4):702-708. PubMed ID: 29667133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of drug-approval regulations for medical countermeasures against CBRN agents in Japan.
    Shimazawa R; Ikeda M
    Health Secur; 2015; 13(2):130-8. PubMed ID: 25813978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Drugs Approved by Public Knowledge-Based Applications (Kouchi-shinsei) During the Last Two Decades in Japan.
    Maeda H; Fukuda Y; Uchida M
    Clin Pharmacol Ther; 2021 Oct; 110(4):1127-1135. PubMed ID: 34110632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
    Nakayama H; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Feb; 33(1):45-52. PubMed ID: 31933266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.